A recombinant adenovirus expressing wild-type bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity

Cancer Biology and Therapy

Volumn 1, Issue 2, 2002, Pages 163-167

  Honda, Tsuyoshi ^a   Kagawa, Shunsuke ^a   Spurgers, Kevin B ^a   Gjertsen, Bjorn T ^a   Roth, Jack A ^a   Fang, Bingliang ^a   Lowe, Stephanie L ^c   Norris, James S ^c   Meyn, Raymond E ^b   McDonnell, Timothy J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenoviral; Androgen; Apoptosis; Bax; Bcl 2; Caspase; Prostate

Indexed keywords

ANDROGEN; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL CULTURE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ADENOVIRIDAE; ANDROGENS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASES; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036491256     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.63     Document Type: Article

References (42)

1. Marchisone C, Pfeffer U, Del Grosso F, Noonan DM, Santi L, Albini A. Progress towards gene therapy for cancer. J Exp Clin Cancer Res 2000; 19:261-270.
2. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89:21-39.
3. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53:4129-4133. (Pubitemid 24146752)
4. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985-991. (Pubitemid 26306836)
5. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, et al. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 1997; 15:2767-72. (Pubitemid 28004566)
6. Marin MC, Hsu B, Meyn RE, Donehower LA, el-Naggar AK, McDonnell TJ. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 1994; 9:3107-3112.
7. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 1994; 14:2556-2563. (Pubitemid 24108238)
8. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-299.
9. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-619. (Pubitemid 23259742)
10. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994; 9:3743-3751. (Pubitemid 24359416)
11. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-1805. (Pubitemid 24163411)
12. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95:4997-5002. (Pubitemid 28208539)
13. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-489. (Pubitemid 27508237)
14. Bruckheimer EM, Gjertsen BT, McDonnell TJ. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 1999; 26:382-398. (Pubitemid 29411447)
15. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res 1995; 1:1295-300.
16. Kagawa S, Pearson SA, Ji L, Xu K, McDonnell TJ, Swisher SG, et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther 2000; 7:75-79. (Pubitemid 30077152)
17. Herrmann JL, Menter DG, Beham A, von Eschenbach A, McDonnell TJ. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. Exp Cell Res 1997; 234:442-4451.
18. Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM, et al. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 1997; 237:101-109. (Pubitemid 27528034)
19. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90:626-630.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
21. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375:78-81.
22. Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5:52-63. (Pubitemid 128639991)
23. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55:5151-5155.
24. Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, et al. Molecular therapy with recombinant p53 adenovirus in an androgen- independent, metastatic human prostate cancer model. Hum. Gene Ther 1996; 7:1683-1691. (Pubitemid 26340481)
25. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J Urol 1997; 158:636-641. (Pubitemid 27327738)
26. Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, et al. Cooperative therapeutic effects of androgen ablation and adenovirus- mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 1999; 6:54-63. (Pubitemid 129667759)
27. Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, et al. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther 1999; 6:313-321. (Pubitemid 129667803)
28. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52:6940-6944. (Pubitemid 23006303)
29. Perez-Stable C, Altman NH, Mehta PP, Deftos LJ, Roos BA. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res 1997; 57:900-906. (Pubitemid 27098015)
30. Bruckheimer EM, Cho S, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene 2000; 19:2404-2412. (Pubitemid 30323473)
31. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone- refractory human prostate cancers. Am. J Pathol 1993; 143:390-400. (Pubitemid 24058194)
32. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148:1567-1576. (Pubitemid 26135897)
33. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55:4438-4445.
34. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996; 56:5594-5599. (Pubitemid 26422158)
35. Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997; 70:341-348. (Pubitemid 27099605)
36. Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, et al. Restoration of bax expression in bax-deficient prostate cancer cells suppresses tumor growth and augments sensitivity to therapeutic cell death induction. Anticancer Res: In Press.
37. Li X, Marani M, Yu J, Nan B, Roth JA, Kagawa S, et al. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res 2001; 61:186-191. (Pubitemid 32095716)
38. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, et al. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 1995; 93:147-155.
39. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81:801-809.
40. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res 1996; 2:1665-1671. (Pubitemid 26356349)
41. Kawabe S, Munshi A, Zumstein LA, Wilson DR, Roth JA, Meyn RE. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non- small cell lung cancer cells but not normal lung fibroblasts. Int J Radiat Biol 2001; 77:185-194. (Pubitemid 32158365)
42. Weill D, Mack M, Roth J, Swisher S, Proksch S, Merritt J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000; 118:966-970.